Gemcitabine induced myositis in patients with pancreatic cancer: case reports and topic review

J Neurooncol. 2012 Jan;106(1):15-21. doi: 10.1007/s11060-011-0672-8. Epub 2011 Aug 3.

Abstract

Gemcitabine potential myotoxicity has been described in several cases of radiation recall and in patients treated with gemcitabine alone or in combination with other chemotherapy agents. We report two cases of gemcitabine related myositis identified at our institution, and perform a literature review of cases which meet the criteria for gemcitabine induced myositis associated to either radiation therapy or chemotherapy alone.

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma / complications*
  • Adenocarcinoma / drug therapy*
  • Adenocarcinoma / pathology
  • Anti-Inflammatory Agents / therapeutic use
  • Antimetabolites, Antineoplastic / adverse effects*
  • Antimetabolites, Antineoplastic / therapeutic use
  • Deoxycytidine / adverse effects
  • Deoxycytidine / analogs & derivatives*
  • Deoxycytidine / therapeutic use
  • Dexamethasone / therapeutic use
  • Female
  • Gemcitabine
  • Humans
  • Magnetic Resonance Imaging
  • Male
  • Middle Aged
  • Muscle, Skeletal / pathology
  • Myositis / chemically induced*
  • Myositis / pathology
  • Pancreatic Neoplasms / complications*
  • Pancreatic Neoplasms / drug therapy*
  • Pancreatic Neoplasms / pathology
  • Radiotherapy / adverse effects
  • Thigh / pathology

Substances

  • Anti-Inflammatory Agents
  • Antimetabolites, Antineoplastic
  • Deoxycytidine
  • Dexamethasone
  • Gemcitabine